![](https://investorshub.advfn.com/uicon/374489.png?cb=1595535472)
Sunday, January 27, 2013 12:08:18 PM
AMBS will have plenty cash soon, its inevitable
SUNNYVALE, CA--(Marketwire - Oct 13, 2011) - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, announced today that it has closed a $10M Equity Funding Facility with Centurion Private Equity, LLC ("Centurion"). The Company will have the ability to draw down on this facility over the course of the next 36 months in tranches of up $750,000, subject to certain conditions and limitations described in the agreement, including limitations based upon the price and trading volume of the Company's common stock, upon the successful registration of the common shares underlying the facility with the Securities & Exchange Commission.
http://www.marketwire.com/press-release/amarantus-biosciences-announces-close-10m-equity-funding-facility-with-centurion-private-otcbb-ambs-1572738.htm
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM